Boehringer Ingelheim GmbH 보도자료
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
06월 15일 11:45
New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in ...
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
06월 13일 11:50
New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared ...
New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
06월 13일 10:50
Results from the MARLINA-T2DTM trial demonstrated that Trajenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company, reduced blood su...
Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
06월 08일 09:55
Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute’s - Harvard Fibrosis Network to discover new wa...
New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound
06월 07일 11:45
Boehringer Ingelheim will announce updated results from the Phase II part of the HM-EMSI-101 [NCT01588145] trial at the Annual Meeting of the American Society of Cli...
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib
06월 03일 11:50
Boehringer Ingelheim has initiated the ELUXA trial programme, designed to further investigate the therapeutic potential of olmutinib* (BI 1482694 / HM61713), a novel...
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
05월 31일 18:45
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan disea...
3 out of 4 people with symptomatic asthma report reduced productivity at work
05월 27일 13:05
Not for distribution to UK/US/Canadian media Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the nega...
IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
05월 25일 11:00
Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational biologic, ...
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
05월 23일 17:50
Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct re...
South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
05월 18일 12:05
Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor...
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
05월 17일 17:30
New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in i...
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
05월 12일 14:15
Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood...
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
05월 11일 18:35
Nine out of 10 patients with atrial fibrillation (AF) surveyed were concerned about the risk of a stroke.[1] Oral anticoagulant (OAC) treatments are usually prescrib...
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
05월 09일 17:05
Boehringer Ingelheim today announced the enrolment of the first patient in the global Phase III trial evaluating the efficacy and safety of nintedanib in combination...
1 2 3 4 5 6 7 8 9 10 11 >
Boehringer Ingelheim GmbH
상장여부 : 비상장
본사 소재지 : INGELHEIM, Germany
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.